A recent study funded by the cancer charity PLANETS has revealed that taking a 2p pill daily can significantly reduce the risk of developing cancer by up to 40%. The study, conducted by researchers at University Hospital Southampton and the University of Southampton, focused on the preventative effects of aspirin in reducing the risk of pancreatic cancer.
The research, which involved nearly 10,000 participants from the UK Biobank, found that regular aspirin intake reduced the risk of pancreatic cancer by 40% in individuals with diabetes and by 20% in the general population. These findings are considered significant, especially given the challenges associated with treating pancreatic cancer, which has one of the lowest survival rates among cancers.
According to a PLANETS spokesman, aspirin has been shown to inhibit the production of enzymes that promote inflammation and cancer cell growth. The study, published in the journal Pancreatology, is believed to be the largest to investigate the association between aspirin use and pancreatic cancer risk.
Dr. Zaed Hamady, a consultant surgeon at University Hospital Southampton, emphasised the importance of these findings, especially for individuals over 50 with diabetes who face a higher risk of developing pancreatic cancer. The study underscores the potential of aspirin as a preventive measure for this deadly cancer, with a 20% risk reduction in the general population and a more substantial 40% reduction in individuals with diabetes.
Pancreatic cancer is known for its poor prognosis, with most cases diagnosed at an advanced stage. The research highlights the significance of regular aspirin use in lowering the risk of developing this aggressive cancer. The study’s results suggest that aspirin, commonly associated with reducing heart-related risks, can also play a vital role in preventing pancreatic cancer.
In conclusion, the study sheds light on the promising preventive benefits of aspirin in reducing the risk of pancreatic cancer. These findings offer hope for improving outcomes for individuals at high risk of developing this challenging cancer.